Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB.

Mov Disord. 2015 Jun;30(7):936-44. doi: 10.1002/mds.26172. Epub 2015 Mar 24.

2.

Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE.

Neurobiol Aging. 2011 Mar;32(3):556.e13-23. doi: 10.1016/j.neurobiolaging.2010.10.020. Epub 2010 Dec 31.

3.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
4.

Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD.

Lebedeva E, Stingl JC, Thal DR, Ghebremedhin E, Strauss J, Özer E, Bertram L, von Einem B, Tumani H, Otto M, Riepe MW, Högel J, Ludolph AC, von Arnim CA.

Neurobiol Aging. 2012 Jan;33(1):201.e9-18. doi: 10.1016/j.neurobiolaging.2010.07.017. Epub 2010 Sep 18.

PMID:
20850903
5.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

PMID:
25971633
6.

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.

Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.

Alzheimers Res Ther. 2016 Jun 30;8:25. doi: 10.1186/s13195-016-0194-x.

7.

Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.

Liguori C, Olivola E, Pierantozzi M, Cerroni R, Galati S, Saviozzi V, Mercuri NB, Stefani A.

CNS Neurol Disord Drug Targets. 2017;16(3):339-345. doi: 10.2174/1871527316666161205123123.

PMID:
27934563
8.

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.

Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK, Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.

Alzheimers Res Ther. 2017 Oct 23;9(1):87. doi: 10.1186/s13195-017-0313-3.

9.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

10.

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.

J Parkinsons Dis. 2015;5(4):783-92. doi: 10.3233/JPD-150682.

11.

Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM.

Neurobiol Aging. 2014 Feb;35(2):357-64. doi: 10.1016/j.neurobiolaging.2013.07.027. Epub 2013 Sep 4.

12.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2014;42(1):157-67. doi: 10.3233/JAD-140240.

PMID:
24820015
13.

Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.

Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H.

Neuromolecular Med. 2012 Mar;14(1):65-73. doi: 10.1007/s12017-012-8171-4. Epub 2012 Feb 18.

PMID:
22350541
14.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

15.

Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.

Abbasi N, Mohajer B, Abbasi S, Hasanabadi P, Abdolalizadeh A, Rajimehr R.

Mov Disord. 2018 Mar;33(3):431-439. doi: 10.1002/mds.27284. Epub 2018 Feb 13.

PMID:
29436735
16.

Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunction.

Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Leverenz J, Fagan A, Goate A, Bateman R, Holtzman DM, Yamamoto T, Nakaya T, Gandy S, Suzuki T.

Ann Neurol. 2011 Jun;69(6):1026-31. doi: 10.1002/ana.22343.

17.

Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.

Vilas D, Shaw LM, Taylor P, Berg D, Brockmann K, Aasly J, Marras C, Pont-Sunyer C, Ríos J, Marek K, Tolosa E.

Mov Disord. 2016 Jun;31(6):906-14. doi: 10.1002/mds.26591. Epub 2016 Apr 4.

PMID:
27041685
18.

Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.

Pyykkö OT, Lumela M, Rummukainen J, Nerg O, Seppälä TT, Herukka SK, Koivisto AM, Alafuzoff I, Puli L, Savolainen S, Soininen H, Jääskeläinen JE, Hiltunen M, Zetterberg H, Leinonen V.

PLoS One. 2014 Mar 17;9(3):e91974. doi: 10.1371/journal.pone.0091974. eCollection 2014.

19.

Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.

Hu X, Yang Y, Gong D.

Neurol Sci. 2017 Nov;38(11):1953-1961. doi: 10.1007/s10072-017-3088-1. Epub 2017 Aug 14. Review.

PMID:
28808876
20.

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.

Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG.

J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. Review.

Supplemental Content

Support Center